Frontpro (previously known as Afoxolaner Merial)

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

afoxolaner

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QP53BE01

INN (International Name):

afoxolaner

Therapeutic group:

psi

Therapeutic area:

Ektoparazitidi za sistemsku uporabu

Therapeutic indications:

Liječenje buha (Ctenocephalides Feliz i C. канис) zaraženosti. Proizvod se može koristiti kao dio strategije liječenja za kontrolu buha alergijskog dermatitisa (FAD). Liječenje grinje (Dermacentor reticulatus, иксодовых ricinusovog, Rhipicephalus sanguineus) zaraženosti. Liječenje demodectic šuge (uzrokovane демодекс канис). Liječenje саркоптозом (bolesti uzrokovane Sarcoptes OPCIJE. Velikog Psa).

Product summary:

Revision: 3

Authorization status:

odobren

Authorization date:

2019-05-20

Patient Information leaflet

                                15
B. UPUTA O VMP
16
UPUTA O VMP :
FRONTPRO 11 MG TABLETA ZA ŽVAKANJE ZA PSE 2–4 KG
FRONTPRO 28 MG TABLETA ZA ŽVAKANJE ZA PSE >4–10 KG
FRONTPRO 68 MG TABLETA ZA ŽVAKANJE ZA PSE >10–25 KG
FRONTPRO 136 MG TABLETA ZA ŽVAKANJE ZA PSE >25–50 KG
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
NJEMAČKA
Nositelj odobrenja za proizvodnju odgovoran za puštanje serije u
promet:
Boehringer Ingelheim Animal Health France SCS
4 Chemin du Calquet
31000 Toulouse
FRANCUSKA
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
FRONTPRO 11 mg tableta za žvakanje za pse (2–4 kg)
FRONTPRO 28 mg tableta za žvakanje za pse (>4–10 kg)
FRONTPRO 68 mg tableta za žvakanje za pse (>10–25 kg)
FRONTPRO 136 mg tableta za žvakanje za pse (>25–50 kg)
afoksolaner
3.
SASTAV DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
Svaka tableta za žvakanje sadrži:
FRONTPRO
Afoksolaner (mg)
tablete za žvakanje za pse 2–4 kg
11,3
tablete za žvakanje za pse >4–10 kg
28,3
tablete za žvakanje za pse >10–25 kg
68,0
tablete za žvakanje za pse >25–50 kg
136,0
Prošarane crvene do smeđe crvenkaste, kružnog (tablete za pse 2–4
kg) ili pravokutnog oblika (tablete
za pse >4–10 kg, tablete za pse >10–25 kg i tablete za pse
>25–50 kg).
4.
INDIKACIJE
Liječenje infestacije buhama u pasa (_Ctenocephalides felis i C.
canis_) do najmanje 5 tjedana.
Proizvod se može koristiti kao dio strategije u suzbijanju
alergijskog dermatitisa pasa uzrokovanog
buhama (FAD).
Liječenje i prevencija infestacije krpeljima u pasa (_Dermacentor
reticulatus, Ixodes ricinus, _
_Rhipicephalus sanguineus_). Jedan tretman ubija krpelje do mjesec
dana.
17
Krpelji i buhe se moraju pričvrstiti na domaćina kako bi bili
izloženi djelovanju djelatne tvari.
Liječenje demodikoze (uzrokovane s _Demodex canis_).
Liječenje Sarcoptes-šuge (uzrokovane s _Sarcoptes scabi
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
FRONTPRO 11 mg tablete za žvakanje za pse 2–4 kg
FRONTPRO 28 mg tablete za žvakanje za pse >4–10 kg
FRONTPRO 68 mg tablete za žvakanje za pse >10–25 kg
FRONTPRO136 mg tablete za žvakanje za pse >25–50 kg
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka tableta za žvakanje sadrži:
DJELATNA TVAR:
FRONTPRO
Afoksolaner (mg)
tablete za žvakanje za pse 2–4 kg
11,3
tablete za žvakanje za pse >4–10 kg
28,3
tablete za žvakanje za pse >10–25 kg
68
tablete za žvakanje za pse >25–50kg
136
Za potpuni popis pomoćnih tvari, vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Tablete za žvakanje.
Prošarane crvene do smeđe crvenkaste, kružnog (tablete za pse 2–4
kg) ili pravokutnog oblika (tablete
za pse >4–10 kg, tablete za pse >10–25 kg i tablete za pse
>25–50 kg).
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Psi.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Liječenje invazije buha u pasa (_Ctenocephalides felis_ i _C. canis_)
do najmanje 5 tjedana. Može se
koristiti kao dio strategije liječenja za kontrolu alergijskog
dermatitisa uzrokovanog buhama (FAD).
Liječenje invazije krpelja u pasa (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_). Jedan tretman ubija krpelje do mjesec dana.
Krpelji i buhe se moraju pričvrstiti na domaćina kako bi bili
izloženi djelovanju djelatne tvari.
Liječenje demodikoze (uzrokovane s _Demodex canis_).
Liječenje Sarcoptes-šuge (uzrokovane sa _Sarcoptes scabiei
_var_.canis_).
4.3
KONTRAINDIKACIJE
Ne koristiti u slučajevima preosjetljivosti na djelatnu tvar ili na
bilo koju od pomoćnih tvari.
3
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Parazit mora započeti hranjenje na domaćinu kako bi započelo
djelovanje afoksolanera, stoga se rizik
od prijenosa krpeljno prenosivih bolesti ne može u potpunosti
isključiti.
4.5
POSEBNE MJERE OPREZA PRILIKOM PRIMJENE
Posebne mjere opreza prilikom primjene na životinjama
U nedostatku do
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-11-2020
Public Assessment Report Public Assessment Report Bulgarian 12-11-2020
Patient Information leaflet Patient Information leaflet Spanish 12-11-2020
Public Assessment Report Public Assessment Report Spanish 12-11-2020
Patient Information leaflet Patient Information leaflet Czech 12-11-2020
Public Assessment Report Public Assessment Report Czech 12-11-2020
Patient Information leaflet Patient Information leaflet Danish 12-11-2020
Public Assessment Report Public Assessment Report Danish 12-11-2020
Patient Information leaflet Patient Information leaflet German 12-11-2020
Public Assessment Report Public Assessment Report German 12-11-2020
Patient Information leaflet Patient Information leaflet Estonian 12-11-2020
Public Assessment Report Public Assessment Report Estonian 12-11-2020
Patient Information leaflet Patient Information leaflet Greek 12-11-2020
Public Assessment Report Public Assessment Report Greek 12-11-2020
Patient Information leaflet Patient Information leaflet English 12-11-2020
Public Assessment Report Public Assessment Report English 12-11-2020
Patient Information leaflet Patient Information leaflet French 12-11-2020
Public Assessment Report Public Assessment Report French 12-11-2020
Patient Information leaflet Patient Information leaflet Italian 12-11-2020
Public Assessment Report Public Assessment Report Italian 12-11-2020
Patient Information leaflet Patient Information leaflet Latvian 12-11-2020
Public Assessment Report Public Assessment Report Latvian 12-11-2020
Patient Information leaflet Patient Information leaflet Lithuanian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-11-2020
Public Assessment Report Public Assessment Report Lithuanian 12-11-2020
Patient Information leaflet Patient Information leaflet Hungarian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 12-11-2020
Public Assessment Report Public Assessment Report Hungarian 12-11-2020
Patient Information leaflet Patient Information leaflet Maltese 12-11-2020
Public Assessment Report Public Assessment Report Maltese 12-11-2020
Patient Information leaflet Patient Information leaflet Dutch 12-11-2020
Public Assessment Report Public Assessment Report Dutch 12-11-2020
Patient Information leaflet Patient Information leaflet Polish 12-11-2020
Public Assessment Report Public Assessment Report Polish 12-11-2020
Patient Information leaflet Patient Information leaflet Portuguese 12-11-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 12-11-2020
Public Assessment Report Public Assessment Report Portuguese 12-11-2020
Patient Information leaflet Patient Information leaflet Romanian 12-11-2020
Public Assessment Report Public Assessment Report Romanian 12-11-2020
Patient Information leaflet Patient Information leaflet Slovak 12-11-2020
Public Assessment Report Public Assessment Report Slovak 12-11-2020
Patient Information leaflet Patient Information leaflet Slovenian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 12-11-2020
Public Assessment Report Public Assessment Report Slovenian 12-11-2020
Patient Information leaflet Patient Information leaflet Finnish 12-11-2020
Public Assessment Report Public Assessment Report Finnish 12-11-2020
Patient Information leaflet Patient Information leaflet Swedish 12-11-2020
Public Assessment Report Public Assessment Report Swedish 12-11-2020
Patient Information leaflet Patient Information leaflet Norwegian 12-11-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 12-11-2020
Patient Information leaflet Patient Information leaflet Icelandic 12-11-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 12-11-2020

Search alerts related to this product